This HTML5 document contains 66 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/AHFS/
n4http://linked.opendata.cz/resource/drugbank/drug/DB06684/identifier/kegg-drug/
n17http://linked.opendata.cz/resource/mesh/concept/
n24http://linked.opendata.cz/resource/drugbank/drug/DB06684/identifier/drugbank/
foafhttp://xmlns.com/foaf/0.1/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n21http://linked.opendata.cz/resource/drugbank/drug/DB06684/identifier/national-drug-code-directory/
n19http://www.rxlist.com/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB06684/identifier/chebi/
n18http://linked.opendata.cz/resource/drugbank/patent/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n16http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n10http://www.drugs.com/cdi/
n22http://linked.opendata.cz/resource/drugbank/drug/DB06684/identifier/wikipedia/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06684
rdf:type
n5:Drug
n5:description
Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors. It has been shown to be equally efficacious as other antidepressants with similar gastrointestinal side effects and possibly with reduced sexual side effects and weight gain. Vilazodone is an antidepressant agent that can used as an alternative for patients who cannot tolerate therapy with other antidepressant classes such as selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors. Treatment should be titrated towards the target dose, which is 40mg per day.
n5:dosage
n8:271B4DF8-363D-11E5-9242-09173F13E4C5 n8:271B4DF9-363D-11E5-9242-09173F13E4C5 n8:271B4DFA-363D-11E5-9242-09173F13E4C5 n8:271B4DFB-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, Reed CR: A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011 Apr;72(4):441-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21527122 # Traynor K: Vilazodone approved for major depression. Am J Health Syst Pharm. 2011 Mar 1;68(5):366. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21330672 # Howland RH: Vilazodone: another novel atypical antidepressant drug. J Psychosoc Nurs Ment Health Serv. 2011 Mar;49(3):19-22. doi: 10.3928/02793695-20110203-98. Epub 2011 Feb 16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21323263 # Dawson LA, Watson JM: Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther. 2009 Summer;15(2):107-17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19499624 # de Paulis T: Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs. 2007 Mar;10(3):193-201. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17351874 # Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, Lucki I: Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carb oxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther. 2002 Sep;302(3):1220-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12183683 # Wang SM, Han C, Lee SJ, Patkar AA, Pae CU: A review of current evidence for vilazodone in major depressive disorder. Int J Psychiatry Clin Pract. 2013 Apr 12. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23578403 # Dopheide JA: Vilazodone's comparative merits yet to be demonstrated. Am J Health Syst Pharm. 2012 Sep 15;69(18):1549. doi: 10.2146/ajhp110570. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22935936
n5:group
approved
n5:halfLife
25.4h
n5:indication
Vilazodone is approved for treatment of acute episodes of major depression. Labeling of vilazodone describes an increased risk of suicidal thoughts in children, adolescents and young adults. The use of vilazodone in pediatrics is not indicated. Its use with monoamine oxidase inhibitors (MAOI) is contraindicated due to increased risk of serotonin syndome. Once the MAOI is discontinued, a 14-day washout period must pass before starting vilazodone.
owl:sameAs
n12:DB06684 n13:DB06684
dcterms:title
Vilazodone
adms:identifier
n4:D09698 n21:0456-1110-30 n22:Vilazodone n23:70707 n24:DB06684
n5:mechanismOfAction
Since serotonin is believed to be one of the three main neurotransmitters that is low or imbalanced in patients with depression- pathways seeking to increase serotonin levels are targeted by pharmaceutical companies. As a selective serotonin reuptake inhibitor, vilazodone prevents serotonin from re-entering cell bodies. Hence, they will remain longer in the synapse. Vilazodone also has an inherent selectivity for serotonin-1A receptors, acting as a partial agonist which stimulates the production of serotonin. The end result is increased serotonin in the synaptic cleft, allowing serotonin to resume its action on nearby cells. The mechanism of the antidepressant effect of vilazodone is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS through selective inhibition of serotonin reuptake.
n5:patent
n18:7834020
n5:routeOfElimination
1% recovered in urine. 2% unchanged in feces.
n5:synonym
Vilazodona Vilazodonum
n5:toxicity
Vomiting, serotonin syndrome.
n14:hasAHFSCode
n15:28-16-04-24
n5:foodInteraction
Gingko bilboa, ginger, garlic, green tea, licorice, horseradish Caution taking vilazodone with foods/herbal product with antiplatelet/anticoagulant properties
n5:proteinBinding
96-99% protein bound
n5:salt
n16:hasConcept
n17:M0477866
foaf:page
n10:vilazodone.html n19:viibryd-drug.htm
n5:IUPAC-Name
n6:271B4E00-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B4E06-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B4E05-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4E02-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4E03-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4E04-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B4DFE-363D-11E5-9242-09173F13E4C5 n6:271B4E16-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B4DFC-363D-11E5-9242-09173F13E4C5 n6:271B4DFF-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B4DFD-363D-11E5-9242-09173F13E4C5
n5:pKa
n6:271B4E17-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n20:N06AX24
n5:H-Bond-Acceptor-Count
n6:271B4E0C-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B4E0D-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B4E07-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B4E08-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B4E0A-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B4E09-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B4E0B-363D-11E5-9242-09173F13E4C5
n5:absorption
Vilazodone's absorption is improved when taken with food to 72%.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
163521-12-8
n5:category
n5:clearance
21.1L/h
n5:Bioavailability
n6:271B4E12-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B4E14-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B4E15-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B4E11-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B4E10-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B4E13-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B4E01-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B4E0E-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B4E0F-363D-11E5-9242-09173F13E4C5